Talis Biomedical Corp: Nasdaq/NYSE listing notice — Talis Biomedical receives 180-day extension to meet Nasdaq $1 bid price rule; deadline July 24, 2023

Talis Biomedical Corp

Transferred stock listing from Nasdaq Global Market to Capital Market on Jan 24, 2023.
Received additional 180-day grace period, until July 24, 2023, to meet $1.00 minimum bid price.
Must have closing bid price at least $1.00 for 10 consecutive business days to regain compliance.
Intends to cure deficiency by effecting a reverse stock split if necessary.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Talis Biomedical Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 24, 2023, the Company transferred the listing of its securities to the Nasdaq Capital Market (the "Capital Market") and received notice from Nasdaq indicating that, while the Company has not regained compliance with the Bid Price Requirement, Nasdaq has determined that the Company is eligible for an additional 180-day period, or until July 24, 2023, to regain compliance. According to the notification from Nasdaq, the Staff’s determination was based on: (i) the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirement

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-001171

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.